1. Academic Validation
  2. Computational analysis reveals non-consensus N-glycosylation sequons in antibody Fab region

Computational analysis reveals non-consensus N-glycosylation sequons in antibody Fab region

  • MAbs. 2025 Dec;17(1):2574406. doi: 10.1080/19420862.2025.2574406.
Baiyu Qiu 1 Edwin Chen 2 Tawnya Flick 1 Simon Letarte 1
Affiliations

Affiliations

  • 1 Biologics Pivotal Analytical Development, Gilead Sciences, Inc ., Oceanside, CA, USA.
  • 2 Biologics Pivotal Process Development, Gilead Sciences, Inc ., Oceanside, CA, USA.
Abstract

Protein glycosylation at asparagine typically occurs at a consensus motif. However, recent studies have reported instances of N-glycosylation at non-consensus sites, though the mechanisms and implications of these atypical modifications remain unclear. In this study, we identified novel non-consensus N-glycosylation motifs with low glycosylation occupancy in the Fab region of human antibodies. We developed a computational workflow to predict the interaction between non-consensus peptides and the eukaryotic oligosaccharyltransferase (OST) complex. This model was validated through site-directed mutagenesis around the asparagine residue and glycosylation quantification via mass spectrometry. Our results show that glycan occupancy at non-consensus sites can be modulated by mutations that influence OST binding affinity. Pharmacological inhibition of OST activity reduced non-consensus and consensus glycosylation in both Fab and Fc regions. Additionally, we identified new non-consensus glycosylation sites in natural human antibodies, revealing the sequence preferences governing these modifications. These findings provide mechanistic insights into OST sequence specificity and establish a computational and analytical framework for assessing atypical N-glycosylation, aiding glycan profile control in therapeutic antibody development.

Keywords

Antibody structure; fab glycosylation; glycan analysis; intravenous immunoglobulin; mass spectrometry; non-consensus N-glycosylation; oligosaccharyltransferase; peptide docking.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-117383
    99.97%, Virus Protease Inhibitor